Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses    
Research and development $ 5,819,461 $ 6,011,805
Cost to acquire IPR&D asset 21,215,214 0
General and administrative 7,852,340 6,094,617
Estimated legal contingency (151,842) 6,205,310
Total operating expenses 34,735,173 18,311,732
Operating loss (34,735,173) (18,311,732)
Other expense    
Change in fair value of derivative liability (3) (59,729)
Interest expense 906,270 665,133
Interest income 99,974 19,011
Finance charge 0 120,228
Loss from asset sale 307,086 0
Debt conversion inducement expense 1,383,285 0
Wind-down costs 409,347 456,508
Total other expense, net 2,906,011 1,163,129
Loss before income taxes (37,641,184) (19,474,861)
Provision for income taxes 3,600 6,741
Net loss $ (37,644,784) $ (19,481,602)
Loss per common share    
Basic (in dollars per share) $ (5.37) $ (8.77)
Diluted (in dollars per share) $ (5.37) $ (8.77)
Weighted average shares of common stock outstanding used to compute loss per share:    
Basic (in shares) 7,006,038 2,221,080
Diluted (in shares) 7,006,038 2,221,080